AbbVie CEO sees hep C market-share grab; FDA deems Roche PDL1 drug a breakthrough; Merck KGaA takes back Russian drug rights;

> AbbVie ($ABBV) expects its hepatitis C drug sales to top $3 billion this year, with CEO Richard Gonzalez predicting Viekira Pak can grab a "meaningful share" of the U.S. market despite competition from Gilead Sciences ($GILD). Report

> The FDA conferred its "breakthrough" designation on Roche's ($RHHBY) anti-PDL1 drug as a treatment for lung cancer; the field is heating up as Merck ($MRK) and Bristol-Myers Squibb ($BMY) vie to be the first with an approved NSCLC immunotherapy. Release

> Keen on emerging markets growth, Merck KGaA took back Russian marketing rights to its diabetes and thyroid franchises from its partner Takeda. Release

> An Arizona court said it would allow a woman with lupus to sue Scottsdale-based Medicis Pharmaceuticals, now a Valeant ($VRX) unit, over alleged risks of its acne drug Solodyn. Report

> The pharma market in France will grow hardly at all over the next several years, GlobalData says, with sales there hitting $48.2 billion by 2020. Report

And Finally... Just how prevalent is "non-personal promotion" in pharma marketing these days? Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.